IDERA PHARMACEUTICALS, INC.

IDERA PHARMACEUTICALS, INC. insiders are currently net buyers of IDRA stock, showing neutral sentiment over the past 90 days. Executives have purchased $47.1M while selling $22.6M, resulting in a positive net flow of $24.5M. This buying activity represents 68% of total transaction volume.

IDERA PHARMACEUTICALS, INC. has 46 active insiders who have filed SEC Form 4 transactions in the past 90 days. Brothers Life Sciences Lp Baker (Executive) leads with 13 transactions totaling $32.2M. Pharmaceuticals Ii, L.p. Pillar (Executive) follows with 26 transactions worth $9.7M. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.

The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. IDERA PHARMACEUTICALS, INC.'s current score of 68/100 indicates neutral insider sentiment. Scores above 60 suggest insiders are accumulating shares faster than selling, reflecting $47.1M in purchases versus $22.6M in sales.

The most recent insider transaction occurred on Jan 11, 2023, when R. Dougherty Michael (Executive) acquired 33,523 shares at $0.44 per share for $14.8K. This appears to be a discretionary trade.

Based on SEC Form 4 filings from the past 90 days, IDRA insider trading sentiment is currently neutral with an Alignment Score of 68/100. The net insider flow of $24.5M reflects accumulation, with 68% of volume being purchases.

SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like IDERA PHARMACEUTICALS, INC.. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At IDRA, we track all Form 4 filings—currently showing 426 transactions from 46 insiders over 90 days.

A 10b5-1 plan allows IDERA PHARMACEUTICALS, INC. executives to pre-schedule stock sales when they don't possess material non-public information. At IDRA, approximately 0% of recent transactions are 10b5-1 trades. Most trading activity at IDRA appears discretionary, making insider signals more meaningful.

You can monitor IDERA PHARMACEUTICALS, INC. (IDRA) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 46 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.

Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. IDERA PHARMACEUTICALS, INC.'s current score of 68/100 indicates moderately bullish sentiment suggesting insider confidence. This is calculated from $47.1M in purchases versus $22.6M in sales over 90 days, resulting in a net flow of $24.5M.

SEC Form 4 filings are mandatory reports that IDERA PHARMACEUTICALS, INC. insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At IDRA, the most common type is "A" with 21 occurrences. The most recent Form 4 was filed on Jan 11, 2023 by R. Dougherty Michael.

Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At IDERA PHARMACEUTICALS, INC., approximately 0% of recent transactions are executed under 10b5-1 plans, while 100% appear to be discretionary trades. The low percentage means most insider activity at IDRA represents discretionary decisions with more informational value.